Is Danaher Corporation (DHR) a Good Long-Term Investment?

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined 6.01% compared to a 4.72% decline for the Russell 3000 Health Care Index. The fund’s underperformance in the quarter was attributed to poor stock selection. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Baron Funds highlighted stocks like Danaher Corporation (NYSE:DHR) in the third quarter 2022 investor letter. Headquartered in Washington, the District of Columbia, Danaher Corporation (NYSE:DHR) operates through Life Sciences, Diagnostics, and Environmental & Applied Solutions segments. On October 17, 2022, Danaher Corporation (NYSE:DHR) stock closed at $259.93 per share. One-month return of Danaher Corporation (NYSE:DHR) was -5.26% and its shares lost 15.74% of their value over the last 52 weeks. Danaher Corporation (NYSE:DHR) has a market capitalization of $189.085 billion.

Here is what Baron Funds specifically said about Danaher Corporation (NYSE:DHR) in its Q3 2022 investor letter:

“We initiated a position in Danaher Corporation (NYSE:DHR). After announcing its intent to spin off its Environmental and Applied Solutions business, Danaher will become a pure play life sciences and diagnostics company. In the life sciences business, Danaher supplies instruments for lab research, genomics services, and bioproduction tools. We are particularly interested in Danaher’s market-leading position and broad portfolio within bioprocessing, which addresses a biologics market that is growing double digits and which we expect to benefit in the near term from a wave of biosimilars entering the market after key patents expire. In the diagnostics business, Danaher offers instruments to run clinical tests in large core labs, hospitals, pathology labs, and at the point of care. Its systems for nucleic acid testing have benefitted in particular from COVID testing, and we think molecular testing at the point of care can continue to drive growth in the diagnostics business. After the separation, we believe Danaher will be a business with 80% recurring revenue and targeting high single-digit organic revenue growth and double-digit EPS growth.”

Danaher Corporation (NYSE:DHR) is not on our list of 30 Most Popular Stocks Among Hedge Funds.  As per our database, 82 hedge fund portfolios held Danaher Corporation (NYSE:DHR)  at the end of the second quarter, which was 83 in the previous quarter.

We discussed Danaher Corporation (NYSE:DHR) in another article and shared the list of diversified dividend stocks to buy. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.